Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ ICU admission 12% Improvement Relative Risk Wang et al. Metformin for COVID-19 Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 16,504 patients in the USA Lower ICU admission with metformin (p=0.0055) Wang et al., BMJ Open Diabetes Research & Care, doi:10.1136/bmjdrc-2021-002299 Favors metformin Favors control
Evaluation and management of COVID-19-related severity in people with type 2 diabetes
Wang et al., BMJ Open Diabetes Research & Care, doi:10.1136/bmjdrc-2021-002299
Wang et al., Evaluation and management of COVID-19-related severity in people with type 2 diabetes, BMJ Open Diabetes Research & Care, doi:10.1136/bmjdrc-2021-002299
Sep 2021   Source   PDF  
  All Studies   Meta
Retrospective 16,504 COVID-19 type 2 diabetes patients, showing lower risk of ICU admission with existing metformin use.
risk of ICU admission, 12.0% lower, RR 0.88, p = 0.005, treatment 6,504, control 10,000, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wang et al., 7 Sep 2021, retrospective, USA, peer-reviewed, 4 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: Original research Evaluation and management of COVID19-­related severity in people with type 2 diabetes Bowen Wang ‍ ‍,1,2 Benjamin S Glicksberg,3,4 Girish N Nadkarni,4,5 Deepak Vashishth1,2 To cite: Wang B, Glicksberg BS, Nadkarni GN, et al. Evaluation and management of COVID19-­related severity in people with type 2 diabetes. BMJ Open Diab Res Care 2021;9:e002299. doi:10.1136/ bmjdrc-2021-002299 ►► Additional supplemental material is published online only. To view, please visit the journal online (http://d​ x.​doi.​ org/​10.​1136/b​ mjdrc-​2021-​ 002299). Received 31 March 2021 Accepted 25 August 2021 © Author(s) (or their employer(s)) 2021. Re-­use permitted under CC BY-­NC. No commercial re-­use. See rights and permissions. Published by BMJ. For numbered affiliations see end of article. Correspondence to Dr Deepak Vashishth; ​vashid@​rpi.e​ du ABSTRACT Introduction People with type 2 diabetes (T2D) have an increased rate of hospitalization and mortality related to COVID-19. To identify ahead of time those who are at risk of developing severe diseases and potentially in need of intensive care, we investigated the independent associations between longitudinal glycated hemoglobin (HbA1c), the impact of common medications (metformin, insulin, ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and corticosteroids) and COVID-19 severity in people with T2D. Research design and methods Retrospective cohort study was conducted using deidentified claims and electronic health record data from the OptumLabs Data Warehouse across the USA between January 2017 and November 2020, including 16 504 individuals with T2D and COVID-19. A univariate model and a multivariate model were applied to evaluate the association between 2 and 3-­year HbA1c average, medication use between COVID-19 diagnosis and intensive care unit admission (if applicable), and risk of intensive care related to COVID-19. Results With covariates adjusted, the HR of longitudinal HbA1c for risk of intensive care was 1.12 (per 1% increase, p<0.001) and 1.48 (comparing group with poor (HbA1c ≥9%) and adequate glycemic control (HbA1c 6%–9%), p<0.001). The use of corticosteroids and the combined use of insulin and metformin were associated with significant reduction of intensive care risk, while ACEIs and ARBs were not associated with reduced risk of intensive care. Conclusions Two to three-­year longitudinal glycemic level is independently associated with COVID-19-­related severity in people with T2D. Here, we present a potential method to use HbA1c history, which presented a stronger association with COVID-19 severity than single-­point HbA1c, to identify in advance those more at risk of intensive care due to COVID-19 in the T2D population. The combined use of metformin and insulin and the use of corticosteroids might be significant to prevent patients with T2D from becoming critically ill from COVID-19.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop